GLP-1 & Heart Health Benefits

The finding that changed how cardiologists view GLP-1

The SELECT trial enrolled over 17,000 people with cardiovascular disease and overweight/obesity — without diabetes — and found semaglutide reduced major adverse cardiovascular events by 20% compared to placebo. This effect appeared early and was not fully explained by weight loss magnitude, suggesting direct cardiovascular protective effects.

What the SELECT trial found

The primary endpoint — cardiovascular death, nonfatal heart attack, and nonfatal stroke — occurred in 6.5% of the semaglutide group vs 8.0% of placebo over approximately 3 years. This 20% relative risk reduction is clinically meaningful and comparable to established cardiovascular medications. Secondary benefits included blood pressure reductions, lipid profile improvements, and lower inflammatory markers.

Mechanisms beyond weight loss

Several mechanisms may explain GLP-1 cardiovascular benefits independent of weight reduction: direct anti-inflammatory effects on blood vessel walls, improved endothelial function, reduced oxidative stress, favorable changes in cardiac metabolism, and reductions in fat surrounding the heart.

Heart rate considerations

GLP-1 medications typically increase resting heart rate by 2-4 beats per minute. This is a known pharmacological effect. For most people, this small increase is not clinically significant. People with certain arrhythmias should discuss this with their provider.